Lomitapide: a review of its clinical use, efficacy, and tolerability
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Lomitapide is an inhibitor of MTP, an enzyme located in the endoplasmic reticulum of hepatocytes and enterocytes. This enzyme is responsible for the synthesis of very low-density lipoproteins in the liver and chylomicrons in the intestine. Lomitapide has been approved by the US Food and Drug Administration, European Medicines Agency, and other regulatory agencies for the treatment of hypercholesterolemia in adult patients with homozygous familial hypercholesterolemia. Clinical trials have shown that lomitapide reduces low-density-lipoprotein cholesterol levels by around 40% in homozygous familial hypercholesterolemia patients on treatment with statins with or without low-density-lipoprotein apheresis, with an acceptable safety and tolerance profile. The most common adverse events are gastrointestinal symptoms that decrease in frequency with long-term treatment, and the increase in liver fat remains stable. This review analyzes the clinical use, efficacy, and tolerability of lomitapide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“MTP facilitates the transfer and loading of triglycerides and phospholipids onto ApoB-100 in hepatic cells’ endoplasmic reticulum. Thereby, the assembly of very-low-density lipoprotein (VLDL) particles, which turn into LDL-C after release into the blood serum, is inhibited.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [155]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lomitapide lowers cholesterol by inhibiting the microsomal triglyceride transfer protein (MTG) [155, 156].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057 · cited 9×
“In >90% of cases, it is caused by mutations in both alleles of LDLR gene, and less frequently in other genes like APOB, PCSK9, and LDLRAP1.(1,2) The estimated prevalence varies from one in 160,000 to 1,000,000 in the general population.”
BackgroundInfluentialCuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1563 · Cited by 632
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Sjouke, B., Kusters, D. M., Kindt, I., Besseling, J., Defesche, J. C., Sijbrands, E. J. G., Roeters van Lennep, J. E., Stalenhoef, A. F. H., Wiegman, A., de Graaf, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu058 · Cited by 443
Cited by
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Chemical Aspects of Human and Environmental Overload with Fluorine
Han, J., Kiss, L., Mei, H., Remete, A. M., Ponikvar-Svet, M., Sedgwick, D. M., Roman, R., Fustero, S., Moriwaki, H., & Soloshonok, V. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01263 · Cited by 537
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Lomitapide lowers cholesterol by inhibiting the microsomal triglyceride transfer protein (MTG) [155, 156].”
BackgroundBarata‐Vallejo, S., & Postigo, A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000856 · Cited by 108
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
Gaudet, D., Greber‐Platzer, S., Reeskamp, L. F., Iannuzzo, G., Rosenson, R. S., Saheb, S., Stefanutti, C., Stroes, E. S. G., Wiegman, A., Turner, T. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae325 · Cited by 92
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
Lohit, N., Singh, A. K., Kumar, A., Singh, H., Yadav, J. P., Singh, K., & Kumar, P. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230224112505 · Cited by 81
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 66
Stefanutti, C. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00858-4 · Cited by 62
Current Understanding on the Role of Lipids in Macrophages and Associated Diseases
Florance, I., & Seenivasan, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010589 · Cited by 54
Vieira, T. F., Magalhães, R. P., Simões, M. V., & Sousa, S. F. (2022) · Antibiotics · doi:10.3390/antibiotics11020185 · Cited by 52
Zubielienė, K., Valterytė, G., Jonaitienė, N., Žaliaduonytė, D., & Zabiela, V. (2022) · Medicina · doi:10.3390/medicina58111665 · Cited by 49
Intracellular Cholesterol Trafficking
Ikonen, E., & Olkkonen, V. M. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041404 · Cited by 46
Nohara, A., Otsubo, Y., Yanagi, K., Yoshida, M., Ikewaki, K., Harada‐Shiba, M., & Jurecka, A. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.45708 · Cited by 43
D’Erasmo, L., Gallo, A., Cefalu, A. B., Costanzo, A. D., Saheb, S., Giammanco, A., Averna, M. R., Buonaiuto, A., Iannuzzo, G., Fortunato, G., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01999-8 · Cited by 38
Lee, B., Park, S. J., Lee, S., Lee, J. W., Lee, E., Yoo, E.-S., Chung, W., Sohn, J., Oh, B., & Kim, S. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05039-6 · Cited by 36
Patel, N. M., Stottlemyer, B. A., Gray, M. P., Boyce, R. D., & Kane‐Gill, S. L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07157-3 · Cited by 32
Gu, J., Gupta, R. N., Cheng, H. K.-H., Xu, Y., & Raal, F. J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae144 · Cited by 32
Wang, S., Qin, L., Liu, F., & Zhang, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02169-0 · Cited by 25
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Liu, S., Ning, Y., Song, W., Sivaguru, P., Wang, Y., Gan, Y., Anderson, E. A., & Bi, X. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202514232 · Cited by 24
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 20
Alonso, R., Arroyo-Olivares, R., Díaz-Díaz, J. L., Fuentes, F. J., Arrieta, F., de Andrés, R., González‐Bustos, P., Argüeso, R., Martín-Ordiales, M., Faedo, C. M., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117516 · Cited by 18
Self-citationGhose, T. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.010 · Cited by 16
Traditional and novel non-statin lipid-lowering drugs
Jain, P. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.003 · Cited by 16
Drug Gene-Set Analysis Identifies Established and Emerging Therapeutic MechanismsPreprint
Bell, N. Y., Uffelmann, E., van Walree, E. S., Schipper, M., Heilbron, K., de Leeuw, C., & Posthuma, D. (2022) · medRxiv · doi:10.1101/2022.09.06.22279660 · Cited by 16
Familial hypercholesterolemia – treatment update in children, systematic review
Ziółkowska, S., Kijek, N., Zendran, I., Szuster, E., & Barg, E. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.116112 · Cited by 15
Gene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 14
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Anagnostis, P. G., Antza, C., Florentin, M., & Kotsis, V. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97845 · Cited by 13
Saeed, M. E. M., Boulos, J. C., MÜCKLICH, S. B., Leich, E., Chatterjee, M., Klauck, S. M., & Efferth, T. (2022) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20339 · Cited by 13
Li, Y., Li, Z., Li, Q., Sun, D., Ni, B., Tan, M., Shay, A. E., Wang, M., Meng, C., Shen, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-68099-0 · Cited by 11
Fan, N., Zhao, F., Meng, Y., Chen, L., Miao, L., Wang, P., Tang, M., Wu, X., Li, Y., Li, Y., et al. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114467 · Cited by 11
Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001011 · Cited by 11
Genome-wide association study of liver fat, iron, and extracellular fluid fraction in the UK BiobankPreprint
O’Dushlaine, C. T., Germino, M., Verweij, N., Nielsen, J. B., Yadav, A. K., Benner, C., Backman, J., Lin, N., Abecasis, G. R., Baras, A., et al. (2021) · medRxiv · doi:10.1101/2021.10.25.21265127 · Cited by 11
Al-Ashwal, A. A., Alsagheir, A., Dubayee, M. A., Al-Khnifsawi, M., Al-Sarraf, A., Awan, Z. A., Ben‐Omran, T., Al-Yaarubi, S., Almutair, A., Habeb, A. M., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.003 · Cited by 10
Hipertrigliceridemia: clasificación, riesgo cardiovascular y conducta terapéutica
Benítez, S. N. G., Díaz, G. E. F., Cabodevilla, R. C. V., Yance, S. F. P., & Rodas, I. G. J. (2020) · Correo Científico Médico · Cited by 9
Kalasin, S., & Surareungchai, W. (2024) · RSC Advances · doi:10.1039/d4ra03965c · Cited by 7
Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.5167/uzh-210372 · Cited by 7
Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications
Alikhani, H. K., Pourhamzeh, M., Seydi, H., Shokoohian, B., Hossein‐Khannazer, N., Jamshidi‐Adegani, F., Al‐Hashmi, S., Hassan, M., & Vosough, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.894800 · Cited by 6
Harada‐Shiba, M., Haruna, S., & Kogawa, N. (2024) · Future Cardiology · doi:10.2217/fca-2023-0136 · Cited by 6
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac104.026032 · Cited by 6
Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia
Pirillo, A., & Catapano, A. L. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac028 · Cited by 6
Lomitapide repurposing for treatment of malignancies: A promising direction
Wu, H.-T., Wu, B., Fang, Z.-X., Wu, Z. L., Hou, Y.-Y., Deng, Y., Cui, Y., & Liu, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32998 · Cited by 5
Son, S. M., Lee, H. S., Kim, J., & Kwon, R. J. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2286 · Cited by 5
Moll, T. O. C., Kiefer, J. G., Klemek, M. L., Wilson, M. H., & Farber, S. A. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322969 · Cited by 4
Rare monogenic disorders of cholesterol metabolism
Bednarska‐Makaruk, M., & Ługowska, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00024-9 · Cited by 4
Current and future trends in the treatment of dyslipidemias
Vrablík, M. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.112 · Cited by 4
Nuevos enfoques terapéuticos de las dislipidemias
Armas, I. O., Lara, A. E., Benítez, S. N. G., Maridueña, E. N. F., & Bravo, J. A. C. (2020) · Correo Científico Médico · Cited by 4
Liu, S., Ning, Y., Song, W., Sivaguru, P., Wang, Y., Gan, Y., Anderson, E. A., & Bi, X. (2025) · Angewandte Chemie · doi:10.1002/ange.202514232 · Cited by 3
The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr−/− Mice with Obesity
Munkhsaikhan, U., Kwon, Y. I., Sahyoun, A. M., Galán, M., González, A. A., Ait‐Aissa, K., Abidi, A. H., Kassan, A., & Kassan, M. (2023) · Antioxidants · doi:10.3390/antiox12061287 · Cited by 3
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Komarov, V. V., Krasnov, V. I., Karpov, V. M., Zonov, Y. V., Parkhomenko, D. A., & Mezhenkova, T. V. (2025) · ChemistrySelect · doi:10.1002/slct.202501998 · Cited by 2
Emerging Pharmacological Therapies in the Management of Hyperlipidemia
Sharma, N., & Roy, S. (2026) · Current Clinical Pharmacology · doi:10.2174/0127724328440604260225063619 · Cited by 2
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Чубыкина, У. В., Владиславович, Е. М., Saidova, M. A., Эмвярович, И. Т., Tmoyan, N. A., Прокопьевич, М. П., Алексеева, И. А., Kabardieva, M. R., Колегаев, А. С., Lepilin, P. M., et al. (2021) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20211602165 · Cited by 2
И., В. С., Мешков, А. Н., Alieva, A. S., & Sonicheva‐Paterson, N. (2023) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2023.04.0001 · Cited by 2
Angel, M., Kleinberg, Y., Newaz, T., Li, V., Zaid, R., Oved, K., Dorot, O., Pichinuk, E., Avitan‐Hersh, E., Saada, A., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03711-6 · Cited by 2
Homozygous familial hypercholesterolemia with an update on cholesterol management
Velvet, A., Soran, H., Clarke, B., Motwani, M., Fath‐Ordoubadi, F., & Daniels, M. J. (2020) · Oxford Medical Case Reports · doi:10.1093/omcr/omaa072 · Cited by 2
Egyptian practical guidance in hypertriglyceridemia management 2021
Taha, H., Kandil, H., Farag, N. M., Oraby, A., Sharkawy, M. E., Fawzy, F., Mahrous, H. A., Bahgat, J., Samy, M., Aboul, M., et al. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00235-9 · Cited by 1
Vieira, T. F., Magalhães, R. P., & Sousa, S. F. (2021) · International Electronic Conference on Synthetic Organic Chemistry (ECSOC) · doi:10.3390/ecsoc-25-11728 · Cited by 1
Gao, M., Yu, W., Hu, H., Liu, H., Fan, K.-J., Gu, C., Wang, L., & Yu, Y. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.535949 · Cited by 1
Pharmacotherapies for Cardiovascular Disease Prevention
Ballard‐Hernandez, J., & Irwin, C. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_14 · Cited by 1
Two Novel Mutations Associated with Familial Chylomicronemia in a Neonate
Jha, V. V., Arora, G., & Arora, V. (2024) · Newborn · doi:10.5005/jp-journals-11002-0105 · Cited by 1
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteins
Kelpsch, D. J., Zhang, L., Thierer, J. H., Cruz, A. G. R., Koren, K., Kumar, U., Lin, Y., Hensley, M. R., Sohn, M., Liu, J. O., et al. (2026) · eLife · doi:10.7554/elife.105314.3 · Cited by 1
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteinsPreprint
Kelpsch, D. J., Zhang, L., Thierer, J. H., Cruz, A. G. R., Koren, K., Kumar, U., Lin, Y., Hensley, M. R., Sohn, M., Liu, J. O., et al. (2025) · eLife · doi:10.7554/elife.105314 · Cited by 1
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteinsPreprint
Kelpsch, D. J., Zhang, L., Thierer, J. H., Koren, K., Kumar, U., Lin, Y., Hensley, M. R., Sohn, M., Liu, J. O., Lectka, T., et al. (2025) · eLife · doi:10.7554/elife.105314.1 · Cited by 1
Lomitapide en hipercolesterolemia familiar heterocigota: reporte de caso
Bedoya-Loaiza, J. E., Romero, A. F., & Amézquita, Y. C. H. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.1.699
Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_5
Advanced therapeutics for targeting atherosclerosis
Bhunia, S. S., & Debnath, U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99988-5.00005-x
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.135
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.136
Trends in Hyperlipidemia Treatments: Summary of Recommendations for Statin and Non-Statin Options
Schultz, P. A., Chaudhri, P., Szymanski, K., Landis, E., & Snyder, J. (2023) · Journal of Family Medicine · doi:10.26420/jfammed.2024.1343
Farmaci innovativi per ridurre il colesterolo LDL: una nuova era nel campo delle dislipidemie
Pepa, G. D. (2024) · il Diabete · doi:10.30682/ildia2403a
Lipid Nanoparticles for Genome Editing in Hypercholesterolemia
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of North Khorasan University of Medical Sciences · doi:10.32592/nkums.17.1.25
Powell, D. R., Sligtenhorst, I. V., Main, A. J., Jin, H., Carson, K. G., Shi, Z.-C., Swaffield, J. C., Smith, M. G., Harris, A. L., Gopinathan, S., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf196
Hypolipidemic and antihyperlipidemic drugs
Vardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00014-4
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Michaeli, D. T. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035637
D’Erasmo, L., Gallo, A., Cefalù, A. B., Costanzo, A. D., Saheb, S., Giammanco, A., Averna, M., Buonaiuto, A., Iannuzzo, G., Fortunato, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16590936
Zone pellucide, cible pour une contraception non hormonale
Rezine Esma, B. M. (2024) · Dépôt Institutionnel de lUniversité de Tlemcen
Caso Clínico: hipercolesterolemia familiar homocigota
Picó Muñoz, R. (2021) · Rovira & Virgili repository
A Heterogeneous Graph Framework for Inference of Metabolite–Protein-Drug Interaction NetworksPreprint
Lu, Y., & C.Sriram, C. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.695016
Comanzo, C. G., Fagalde, F. B., Vera, M. C., Bustos, L. O., Palma, N. F., Capiglioni, A. M., Hesse, L. D., Pisani, G. B., Ferretti, A. C., Ceballos, M. P., et al. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104301
Discovery of Lomitapide as a Novel Mast Cell Regulatory Agent Through Chemical Library Screening
Mamorita, S., Furukawa, A., Nagata, Y., & Suzuki, R. (2026) · European Journal of Immunology · doi:10.1002/eji.70152
Liu, Y., Zhao, F.-Y., Wang, J., Li, B., Lu, S., Li, C., & Wang, H. (2026) · iScience · doi:10.1016/j.isci.2026.115316
Majchrowicz, G., Jońca, M., Kurys, N., Piekarska, W., & Litke, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5095
Karungi, I., Holven, K. B., Ray, K. K., & Elshorbagy, A. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01431-1
Duan, Y., Gong, K., & Wang, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.01002-1
Canepari, C. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Metadata
- Authors
- Alonso, R., Cuevas, A., & Mata, P.
- Affiliations
- Clínica Las Condes (CL)
- ORCID
- Cuevas, Ada
- Venue
- Core Evidence
- Publisher
- Informa UK Limited
- Published
- 2019-07
- Volume
- Volume 14
- Pages
- 19-30
- ISSN
- 1555-1741 (ISSN-L)
- 1555-175X
- PMC
- PMC6615460
- OpenAlex
- W2954216456
- Semantic Scholar
- 1650974f40548e244d10ba65a393c129a29a75bd
- Cited by
- 81
- References
- 42
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 14 · 2023: 10 · 2022: 14 · 2021: 11 · 2020: 8 · 2019: 1
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Core evidence (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lomitapide, microsomal triglyceride transfer protein inhibitor, homozygous familial hypercholesterolemia, hypercholesterolemia, LDL cholesterol lowering, statin combination therapy, LDL apheresis, drug safety and tolerability, gastrointestinal adverse effects, hepatic steatosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.